Oncology
Refine Search
Biotechnology
Insights from Jeevan Virk, UK and Ireland general manager of Advanced Accelerator Applications. 18 August 2020
Biosimilars
Shanghai Henlius Biotech says that its trastuzumab biosimilar HLX02, developed and manufactured by Henlius independently, has been approved by China’s National Medical Products Administration (NMPA), referencing Roche’s blockbuster cancer drug Herceptin. 17 August 2020
Biotechnology
Bristol Myers Squibb’s Opdivo (nivolumab) is set to become the market leader in gastric in gastro-oesophageal cancer following the latest data from two label expansion trials, which were noted to have met their primary endpoints. 14 August 2020
Biotechnology
Shares in Swedish biotech Isofol Medical looked set to close more than 30% higher on Thursday. 13 August 2020
Biotechnology
US biotech Seattle Genetics says that Australian regulatory authorities have approved marketing of Tukysa (tucatinib) in combination with trastuzumab and capecitabine. 13 August 2020
Biotechnology
Danish biotech success story Genmab was 3% higher as Thursday’s trading entered its final third. 13 August 2020
Biotechnology
Privately-held UK oncology company Celleron Therapeutics has paid for worldwide rights to Roche’s emactuzumab. 13 August 2020
Biotechnology
Shares of Japanese drugmaker Eisai closed up 13.7% at 9.811 yen yesterday, after it announced top-line results from Study 211, a Phase II trial evaluating the efficacy and safety of Lenvima (lenvatinib). 12 August 2020
Biotechnology
Japan’s Daiichi Sankyo has entered into a clinical trial collaboration with UK-based AstraZeneca to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), and AstraZeneca’s Tagrisso (osimertinib), 11 August 2020
Biotechnology
Investors initially reacted positively to Verastem's proposed licensing deal for Copiktra (duvelisib), sending the US biotech firm’s shares up 6.4% to $1.58, but soon lost interest, leaving the stock hardly changed by late morning. 10 August 2020
Biotechnology
US clinical-stage biotech Pieris Pharmaceuticals saw its shares gain more than 18% to $3.19 in pre-market trading today, after it announced a clinical trial collaboration and supply agreement US pharma major Eli Lilly. 10 August 2020
Biosimilars
Samsung Bioepis today announced the launch of its first oncology treatment Ontruzant (trastuzumab), a biosimilar referencing Herceptin, in Brazil. 10 August 2020
Pharmaceutical
Spanish drugmaker PharmaMar has entered into a licensing agreement with Onko Ilac San ve Tic to commercialize its marine-derived anticancer drug Yondelis (trabectedin) in Turkey. 10 August 2020
Pharmaceutical
Last week’s notable regulatory news included Germany’s MorphoSys and US partner Incyte gaining approval from the US Food and Drug Administration for their B-cell lymphoma drug Monjuvi (tafasitamab). Also, GlaxoSmithKline’s return to the oncology sector was rewarded last week with FDA approval for its Blenrep (belantamab mafodotin), the first ever anti-BCMA agent. Among research developments, Immunic released positive Phase II data for its IMU-838 in the treatment of relapsing-remitting multiple sclerosis (RRMA), and Denmark’s Lundbeck announced the discontinuation of its Phase II study of Lu AF11167 in schizophrenia. Deal-making featured a potential $2 billion agreement for Biogen to acquire rights to a Parkinson’s disease program from Denali Therapeutics 9 August 2020
Pharmaceutical
A collaboration between Japan’s Daiichi Sankyo and the UK’s AstraZeneca will test patritumab deruxtecan, a novel antibody-drug conjugate (ADC), with Tagrisso (osimertinib). 7 August 2020
Pharmaceutical
Australia’s Kazia Therapeutics has been awarded Rare Pediatric Disease Designation (RPDD) for paxalisib (formerly GDC-0084) by the US regulator. 7 August 2020
Biotechnology
In the second quarter of 2020, the acquisition of rival cancer specialist Celgene drove revenues at Bristol-Myers Squibb to $10.1 billion, a rise of 61% on the same period of 2019 and roughly what analysts were expecting. 6 August 2020
Biotechnology
A more upbeat financial results statement from Germany’s Merck KGaA reflects rebounding sales in key markets, with falling COVID-19 rates enabling countries to relax lockdown measures. 6 August 2020
Biotechnology
Efforts from UK drugmaker GlaxoSmithKline to expand its interests in oncology have started to bear fruit, with US approval for a first-in-class antibody-drug conjugate. 6 August 2020
Generics
Israel’s largest drugmaker and generics giant Teva Pharmaceutical beat analysts’ profit forecasts for the second quarter, with a slightly smaller dip in profits at $1.8 billion. 5 August 2020
Biotechnology
Research news last week included US biotech releasing early data for its FT819 in the treatment of systemic lupus erythematosus (SLE), which sent the firm’s shares leaping as much as 70%. Also, Netherlands-based NewAmsterdam Pharma announced positive data on its obicetrapib and ezetimibe combination in cardiovascular disease. On the regulatory front, Dutch firm argenX and China’s Zai Lab gained approval from the Chinese medicines regulator for their Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) care. Meantime, USA-based Kura Oncology signed a collaboration with Japan’s Kyowa Kirin on the development of ziftomenib for myeloid leukemia (ALS). 24 November 2024
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze